IXI Ixico Plc

TIDMIXI

IXICO plc

16 March 2020

16 March 2020

IXICO plc

("IXICO" or the "Company")

IXICO announces an expanded contract for its imaging services with Vaccinex

Supports Vaccinex's diversification into clinical development of pepinemab for Alzheimer's disease

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an award of a contract to provide imaging services for Vaccinex Inc.'s (Nasdaq: VCNX) planned Phase Ib/IIa trial of pepinemab, a potential treatment of Alzheimer's disease (AD). This will build on the Company's existing contract to support Vaccinex's Phase II study of pepinemab in the Huntington's disease SIGNAL trial, which was previously announced in September 2017.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"This AD trial, called SIGNAL - AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes.

"We are delighted that Vaccinex has chosen to expand our partnership to support its diversification into Alzheimer's disease. Our existing project with Vaccinex, the SIGNAL trial, is in Huntington's disease (HD) to study the safety and efficacy of pepinemab, where the positive imaging results obtained in an interim cohort analysis indicated its potential in additional therapeutic areas; this contract was initiated in 2017 and the new award is a great testament to the achievements of our two organisations working diligently together since then. We are pleased to be part of Vaccinex's effort to bring hope to AD patients and their families."

This contract does not have significant impact on management's expectations of perfomance for the year.

For further information please contact:

 
 IXICO plc                                   +44 (0) 20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 Optimum Strategic Communications            +44 (0) 203 950 9144 
 Mary Clark, Supriya Mathur, Manel Mateus 
 IXICO@optimumcomms.com 
 

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

About Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in non-small cell lung cancer and Huntington's disease. Vaccinex is based in Rochester, New York.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRABSGDXIXBDGGX

(END) Dow Jones Newswires

March 16, 2020 05:00 ET (09:00 GMT)

Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024